Aurora Financial Journal

AbbVie Inc. (ABBV)

NYSE · Health care · Pharmaceutical Preparations · Financial statements, TTM figures and earnings dates

AbbVie Inc. reported revenue of $64.39B over the trailing twelve months ended June 30, 2026, with net income of $6.31B. Annual financial statements are available for fiscal years 2011 to 2025, taken from the company's filings with the SEC. The next quarterly results release is estimated for January 6, 2027, based on the company's filing history.

Open interactive financials →

Key financials

USDTTM
2026-06-30
FY2025
2025-12-31
FY2024
2024-12-31
FY2023
2023-12-31
FY2022
2022-12-31
FY2021
2021-12-31
Income statement
Revenue$64.39B$61.16B$56.33B$54.32B$58.05B$56.20B
Gross profit–$42.96B$39.43B$33.90B$40.64B$38.75B
Operating income$16.87B$15.07B$9.14B$12.76B$18.12B$17.92B
Net income$6.31B$4.23B$4.28B$4.86B$11.84B$11.54B
Diluted EPS$3.54$2.36$2.39$2.72$6.63$6.45
Cash flow
Operating cash flow$19.51B$19.03B$18.81B$22.84B$24.94B$22.78B
Capital expenditure$1.30B$1.21B$974.0M$777.0M$695.0M$787.0M
Free cash flow$18.21B$17.82B$17.83B$22.06B$24.25B$21.99B
Balance sheet
Cash and equivalents$6.57B$5.23B$5.52B$12.81B$9.20B$9.75B
Total assets$135.12B$133.96B$135.16B$134.71B$138.81B$146.53B
Total liabilities$141.00B$137.19B$131.80B$124.31B$121.52B$131.09B
Total debt$70.82B$67.00B$66.84B$59.24B$63.13B$75.98B
Shareholders' equity−$5.93B−$3.27B$3.33B$10.36B$17.25B$15.41B

TTM = trailing twelve months (balance-sheet items at the latest quarter end). Figures in USD as reported; per-share data adjusted for stock splits.

Annual reports

More on the interactive page

The full ABBV page on Aurora Financial Journal includes every fiscal year since the company began filing structured data, income statement, balance sheet and cash flow statement line by line, the statements exactly as filed with the SEC, charts for every measure, valuation multiples (P/E, P/S, P/B), live price charts and the earnings calendar.

Open ABBV financials →